Utility of 3'-[(18)F]fluoro-3'-deoxythymidine As a PET Tracer to Monitor Response to Gene Therapy in a Xenograft Model of Head and Neck Carcinoma

Overview

Journal Am J Nucl Med Mol Imaging

Date 2013 Jan 24

PMID 23342298

Citations 5

Authors

Neale S Mason

Brian J Lopresti

James Ruszkiewicz

Xinxin Dong

Sonali Joyce

George Leef

Malabika Sen

Abdus S Wahed

Chester A Mathis

Jennifer R Grandis

Sufi M Thomas

Affiliations

Soon will be listed here.

Abstract

Noninvasive imaging methodologies are needed to assess treatment responses to novel molecular targeting approaches for the treatment of squamous cell carcinoma of the head and neck (SCCHN). Computer tomography and magnetic resonance imaging do not effectively distinguish tumors from fibrotic tissue commonly associated with SCCHN tumors. Positron emission tomography (PET) offers functional non-invasive imaging of tumors. We determined the uptake of the PET tracers 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) and 3'-[(18)F]Fluoro-3'-deoxythymidine ([(18)F]FLT) in several SCCHN xenograft models. In addition, we evaluated the utility of [(18)F]FLT microPET imaging in monitoring treatment response to an EGFR antisense approach targeted therapy that has shown safety and efficacy in a phase I trial. Two of the 3 SCCHN xenograft models tested demonstrated no appreciable uptake or retention of [(18)F]FDG, but consistent accumulation of [(18)F]FLT. The third tumor xenograft SCCHN model (Cal33) demonstrated variable uptake of both tracers. SCCHN xenografts (1483) treated with EGFR antisense gene therapy decreased tumor volumes in 4/6 mice. Reduced uptake of [(18)F]FLT was observed in tumors that responded to epidermal growth factor antisense (EGFRAS) gene therapy compared to non-responding tumors or tumors treated with control sense plasmid DNA. These findings indicate that [(18)F]FLT PET imaging may be useful in monitoring SCCHN response to molecular targeted therapies, while [(18)F]FDG uptake in SCCHN xenografts may not be reflective of the level of metabolic activity characteristic of human SCCHN tumors.

Citing Articles

measurement of glucose uptake after radiation and cetuximab treatment in head and neck cancer cell lines using 18F-FDG, gamma spectrometry and PET/CT.

Matic N, Ressner M, Wiechec E, Roberg K Oncol Lett. 2019; 18(5):5155-5162.

PMID: 31620196 PMC: 6788167. DOI: 10.3892/ol.2019.10916.

In vivo evaluation of the effects of simultaneous inhibition of GLUT-1 and HIF-1α by antisense oligodeoxynucleotides on the radiosensitivity of laryngeal carcinoma using micro 18F-FDG PET/CT.

Shen L, Zhao X, Zhou S, Lu Z, Zhao K, Fan J Oncotarget. 2017; 8(21):34709-34726.

PMID: 28410229 PMC: 5471005. DOI: 10.18632/oncotarget.16671.

F-FLT and F-FDG PET-CT imaging in the evaluation of early therapeutic effects of chemotherapy on Walker 256 tumor-bearing rats.

Xu W, Yu S, Xin J, Guo Q Exp Ther Med. 2017; 12(6):4154-4158.

PMID: 28101193 PMC: 5228162. DOI: 10.3892/etm.2016.3869.

Utility of [18 F]FLT-PET to assess treatment response in trastuzumab-resistant and trastuzumab-sensitive HER2-overexpressing human breast cancer xenografts.

Whisenant J, McIntyre J, Peterson T, Kang H, Sanchez V, Manning H Mol Imaging Biol. 2014; 17(1):119-28.

PMID: 25034624 PMC: 4311727. DOI: 10.1007/s11307-014-0770-z.

Multimodality imaging of RNA interference.

Nayak T, Krasteva L, Cai W Curr Med Chem. 2013; 20(29):3664-75.

PMID: 23745567 PMC: 3749287. DOI: 10.2174/0929867311320290012.

References

Tseng J, Kang K, Dandekar M, Yaghoubi S, Lee J, Christensen J . Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET. J Nucl Med. 2007; 49(1):129-134. PMC: 4161137. DOI: 10.2967/jnumed.106.038836. View

Fleming Jr A, Smith Jr S, Paul C, Hall N, Daly B, Agrawal A . Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope. 2007; 117(7):1173-9. DOI: 10.1097/MLG.0b013e31805d017b. View

Dandekar M, Tseng J, Gambhir S . Reproducibility of 18F-FDG microPET studies in mouse tumor xenografts. J Nucl Med. 2007; 48(4):602-7. PMC: 4161128. DOI: 10.2967/jnumed.106.036608. View

Schwartz D, Rajendran J, Yueh B, Coltrera M, Anzai Y, Krohn K . Staging of head and neck squamous cell cancer with extended-field FDG-PET. Arch Otolaryngol Head Neck Surg. 2003; 129(11):1173-8. DOI: 10.1001/archotol.129.11.1173. View

Nam S, Lee S, Im K, Kim J, Kim S, Choi S . Early evaluation of the response to radiotherapy of patients with squamous cell carcinoma of the head and neck using 18FDG-PET. Oral Oncol. 2005; 41(4):390-5. DOI: 10.1016/j.oraloncology.2004.10.005. View

Bao A, Phillips W, Goins B, McGuff H, Zheng X, Woolley F . Setup and characterization of a human head and neck squamous cell carcinoma xenograft model in nude rats. Otolaryngol Head Neck Surg. 2006; 135(6):853-7. DOI: 10.1016/j.otohns.2006.06.1257. View

Fueger B, Czernin J, Hildebrandt I, Tran C, Halpern B, Stout D . Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med. 2006; 47(6):999-1006. View

Revheim M, Roe K, Bruland O, Bach-Gansmo T, Skretting A, Seierstad T . Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT. Mol Imaging Biol. 2010; 13(6):1234-40. PMC: 3210949. DOI: 10.1007/s11307-010-0464-0. View

Ma W, Jacene H, Song D, Vilardell F, Messersmith W, Laheru D . [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol. 2009; 27(16):2697-704. PMC: 2689846. DOI: 10.1200/JCO.2008.18.8383. View

10.

Pauwels E, Sturm E, Bombardieri E, Cleton F, Stokkel M . Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol. 2000; 126(10):549-59. DOI: 10.1007/pl00008465. View

11.

Anzai Y, Carroll W, Quint D, Bradford C, Minoshima S, Wolf G . Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology. 1996; 200(1):135-41. DOI: 10.1148/radiology.200.1.8657901. View

12.

Gordin A, Golz A, Daitzchman M, Keidar Z, Bar-Shalom R, Kuten A . Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging in patients with carcinoma of the nasopharynx: diagnostic accuracy and impact on clinical management. Int J Radiat Oncol Biol Phys. 2007; 68(2):370-6. DOI: 10.1016/j.ijrobp.2006.12.028. View

13.

Dence C, Ponde D, Welch M, Lewis J . Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer. Nucl Med Biol. 2008; 35(6):713-20. PMC: 2661147. DOI: 10.1016/j.nucmedbio.2008.06.001. View

14.

Vera P, Bohn P, Edet-Sanson A, Salles A, Hapdey S, Gardin I . Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in.... Radiother Oncol. 2010; 98(1):109-16. DOI: 10.1016/j.radonc.2010.10.011. View

15.

von Forstner C, Egberts J, Ammerpohl O, Niedzielska D, Buchert R, Mikecz P . Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer. J Nucl Med. 2008; 49(8):1362-70. DOI: 10.2967/jnumed.107.050021. View

16.

Su H, Seimbille Y, Ferl G, Bodenstein C, Fueger B, Kim K . Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors. Eur J Nucl Med Mol Imaging. 2008; 35(6):1089-99. DOI: 10.1007/s00259-007-0636-6. View

17.

Bjurberg M, Henriksson E, Brun E, Ekblad L, Ohlsson T, Brun A . Early changes in 2-deoxy-2-[18F]fluoro-D-glucose metabolism in squamous-cell carcinoma during chemotherapy in vivo and in vitro. Cancer Biother Radiopharm. 2009; 24(3):327-32. DOI: 10.1089/cbr.2008.0556. View

18.

Reske S, Grillenberger K, Glatting G, Port M, Hildebrandt M, Gansauge F . Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med. 1997; 38(9):1344-8. View

19.

Linecker A, Kermer C, Sulzbacher I, Angelberger P, Kletter K, Dudczak R . Uptake of (18)F-FLT and (18)F-FDG in primary head and neck cancer correlates with survival. Nuklearmedizin. 2008; 47(2):80-5. DOI: 10.3413/nukmed-0092. View

20.

Minn H, Clavo A, Wahl R . Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol. 1996; 23(8):941-6. DOI: 10.1016/s0969-8051(96)00134-5. View